FTSE Factsheet - London Stock Exchange

FTSE COMPANY REPORT
Share price analysis relative
to sector and index performance
Midatech Pharma
Data as at: 28 September 2016
MTPH
Pharmaceuticals & Biotechnology — GBP 1.29 at close 28 September 2016
Absolute
Relative to FTSE UK All-Share Sector
28-Sep-2016
Relative Price
2
1.5
1
Sep-2015
Dec-2015
Absolute Price
Mar-2016
4-wk mov.avg.
Jun-2016
Sep-2016
100
100
90
90
80
80
70
60
50
50
40
40
30
30
Dec-2015
Relative Price
Mar-2016
4-wk mov.avg.
Jun-2016
Sep-2016
RSI (Relative to FTSE UK All-Share Sector)
80
70
60
50
40
30
20
10
0
80
70
60
50
40
30
20
10
0
Dec-2015
Mar-2016
Jun-2016
Sep-2016
Sep-2015
MTD
YTD
-3.7
-4.4
-4.3
-6.2
-5.5
-5.4
-22.1
-24.7
-22.8
-25.9
-35.2
-31.6
Trailing
Dec-2015
Mar-2016
Jun-2016
Sep-2016
PE
-ve
EV/EBITDA
-ve
PCF
-ve
PB
1.2
Price/Sales
+ve
Div Yield
0.0
Div Payout
0.0
100
ROE
-ve
90
Net Debt/Equity
0.0
Relative Price
100
WTD
VALUATION
Sep-2015
13-wk mov.avg.
90
Absolute
Rel.Sector
Rel.Market
1D
70
60
13-wk mov.avg.
90
RSI (Absolute)
110
Sep-2015
100
Sep-2015
110
RSI (Relative to FTSE UK All-Share Index)
Absolute Price (local currency)
2.5
28-Sep-2016
Relative Price
3
PERFORMANCE
Relative to FTSE UK All-Share Index
28-Sep-2016
4-wk mov.avg.
13-wk mov.avg.
80
70
DESCRIPTION
60
50
The Company is a UK incorporated nanomedicine
company focused on the development and
commercialisation of multiple therapeutic products to
enhance the delivery of medicines in major diseases
with high unmet medical needs
40
30
20
10
0
Dec-2015
Mar-2016
Jun-2016
Sep-2016
Sep-2015
Dec-2015
Mar-2016
Jun-2016
Sep-2016
See final page and http://www.londonstockexchange.com/prices-and-markets/stocks/services-stock/ftse-note.htm for further details.
Past performance is no guarantee of future results. Please see the final page for important legal disclosures.
1 of 4
FTSE COMPANY REPORT: Midatech Pharma
28 September 2016
Valuation Metrics
Price to Earnings (PE)
EV to EBITDA
Price to Book (PB)
31-Aug-2016
31-Aug-2016
1
1
0.9
0.9
0.8
0.8
0.7
0.7
0.6
0.6
0.5
0.5
0.4
0.4
0.3
0.3
0.2
0.2
0.1
+1SD
1.5
Avg
1
-1SD
0.5
0.1
ǁ
0
Sep-2011
31-Aug-2016
2
Sep-2012
Vectura Group
Dechra Pharmaceuticals
Shire
BTG
AstraZeneca
Pharmaceuticals & Biotechnology
Indivior
GlaxoSmithKline
Circassia Pharmaceuticals
Midatech Pharma
Oxford Biomedica
Sep-2013
Sep-2014
ǁ
Sep-2015
120.0
61.9
47.6
37.9
33.4
16.9
15.3
9.5
-5.4
-5.4
-8.7
-20
0
20
40
60
80
100
120
ǁ
0
Sep-2011
Sep-2012
Vectura Group
Dechra Pharmaceuticals
Shire
BTG
Genus
Pharmaceuticals & Biotechnology
GlaxoSmithKline
Indivior
Circassia Pharmaceuticals
Midatech Pharma
Oxford Biomedica
140
Price to Cash Flow (PCF)
Sep-2013
Sep-2014
ǁ
Sep-2015
14.1
11.1
9.6
0.0
0.0
0.0
0
5
10
15
20
25
30
35
40
45
Dividend Yield %
31-Aug-2016
0.9
0.8
0.8
14
0.7
0.7
0.6
0.6
10
0.5
0.5
8
0.4
0.4
0.3
0.3
6
0.2
0.2
0.1
0.1
Sep-2013
GlaxoSmithKline
Pharmaceuticals & Biotechnology
Genus
Dechra Pharmaceuticals
Vectura Group
AstraZeneca
BTG
Indivior
Midatech Pharma
Circassia Pharmaceuticals
Oxford Biomedica
Sep-2014
ǁ
Sep-2015
10.9
-4.4
-5.1
-8.7
-20
-10
0
10
20
30
40
3.5
2.7
1.2
0.7
0.0
2
4
6
8
10
12
50
14
16
18
ǁ
ǁ
4
2
0
Sep-2012
Sep-2013
GlaxoSmithKline
AstraZeneca
Pharmaceuticals & Biotechnology
Indivior
Dechra Pharmaceuticals
Genus
Vectura Group
Oxford Biomedica
Midatech Pharma
Circassia Pharmaceuticals
BTG
41.7
31.5
29.7
29.4
27.8
27.4
24.0
6.3
6.2
5.7
12
0
Sep-2011
15.6
10.4
31-Aug-2016
0.9
Sep-2012
Sep-2015
31-Aug-2016
16
Sep-2011
Sep-2014
7.3
0
1
ǁ
Sep-2013
Price to Sales (PS)
1
0
Sep-2012
GlaxoSmithKline
Oxford Biomedica
Pharmaceuticals & Biotechnology
Shire
Dechra Pharmaceuticals
Hikma Pharmaceuticals
Genus
BTG
Midatech Pharma
Circassia Pharmaceuticals
Indivior
39.7
24.8
23.1
22.6
22.3
ǁ ǁ
0
Sep-2011
Sep-2014
Sep-2015
Sep-2011
3.3
3.0
1.2
1.1
0.0
0.0
0.0
0.0
0.0
0
1
2
3
4
5
Sep-2013
Midatech Pharma
Circassia Pharmaceuticals
Vectura Group
Shire
Oxford Biomedica
BTG
Pharmaceuticals & Biotechnology
AstraZeneca
Indivior
GlaxoSmithKline
Genus
4.9
3.8
Sep-2012
6
Sep-2014
Sep-2015
15.0
15.0
12.8
9.9
7.1
5.1
4.2
3.8
3.4
3.3
2.8
0
2
4
6
8
10
12
14
16
Note: bar chart reflects the top and bottom five current values for the valuation ratio in question for FTSE All Shares stocks in the same sector as the stock concerned. All valuation metrics are trailing.
2 of 4
FTSE COMPANY REPORT: Midatech Pharma
28 September 2016
Valuation Metrics
Net Debt to Equity
Dividend Payout (DP)
Return on Equity (RoE)
31-Aug-2016
31-Aug-2016
0.0465
31-Aug-2016
1
1
0.9
0.9
0.8
0.8
0.0455
0.7
0.7
0.045
0.6
0.6
0.0445
0.5
0.5
0.4
0.4
0.3
0.3
0.2
0.2
0.1
0.1
0.046
0.044
0.0435
0.043
0
Sep-2011
Sep-2012
Sep-2013
GlaxoSmithKline
Oxford Biomedica
Pharmaceuticals & Biotechnology
AstraZeneca
Hikma Pharmaceuticals
Genus
Shire
Midatech Pharma
Vectura Group
Circassia Pharmaceuticals
BTG
Sep-2014
Sep-2015
0.8
0.5
0.3
0.2
0.0
0.0
0.0
0.0
0
0.5
1
1.5
2
2.5
3
Sep-2012
Sep-2013
AstraZeneca
Dechra Pharmaceuticals
Pharmaceuticals & Biotechnology
GlaxoSmithKline
Indivior
Genus
Vectura Group
Shire
Oxford Biomedica
Midatech Pharma
Circassia Pharmaceuticals
BTG
3.3
2.5
1.1
ǁ
0
Sep-2011
29.6
0.0
0.0
0.0
0.0
0.0
0.0
0
3.5
20
ROE vs. PB — sector
Sep-2014
40
Sep-2015
63.3
57.5
39.9
60
Sep-2011
GlaxoSmithKline
Pharmaceuticals & Biotechnology
Hikma Pharmaceuticals
AstraZeneca
Shire
Genus
BTG
Vectura Group
Circassia Pharmaceuticals
Midatech Pharma
Oxford Biomedica
100.0
76.6
80
100
Sep-2012
120
Sep-2013
Sep-2014
ǁ
Sep-2015
50.0
44.3
19.7
14.7
14.3
13.4
7.5
2.2
-16.5
-22.4
-50.0
-60
-40
-20
0
20
40
60
Du Pont Analysis
10
18
1
0.9
16
GSK
0
0.8
14
PB
0.7
-10
12
0.6
OXB
10
-20
0.5
0.4
8
Pharmaceuticals
DPH
6
SHP
-30
AZN
4
VEC
0.3
HIK
0.2
-40
GNS
0.1
BTG
2
0
0
ǁ
-50
MTPH
CIR
2012
10
20
30
40
50
60
2013
Net Margin
2014
Asset Turnover
2015
Gearing
0
2016
ROE (rhs)
ǁ
ROE
Note: bar chart reflects the top and bottom five current values for the valuation ratio in question for FTSE All Shares stocks in the same sector as the stock concerned. All valuation metrics are trailing.
3 of 4
FTSE COMPANY REPORT: Midatech Pharma
28 September 2016
Brief description
Brief description
Price to Earnings
(PE)
Price to Earnings (PE) is price over earnings per share. Earnings are based on the latest
available fiscal year earnings.
Gearing
Gearing is Total Assets divided by Common Equity. Total Assets and Common Equity are
each averaged over two years, that is, t and (t-1).
Price to Sales (PS)
Price to Sales (PS) is price divided by sales per share. It is based on sales from continuing
operations for the fiscal year.
Asset Turnover
Asset turnover is Sales divided by Total Assets. Total Assets is averaged over two years,
that is, t and (t-1).
Price to Book (PB)
Price to Book (PB) is price at the indicated date divided by common equity per share.
Common/ordinary equity is generally as reported at the most recent fiscal year-end but is
adjusted to exclude minority interest, preferred stock and selected items as appropriate.
Dupont Breakdown
Analysis
Return on Equity (RoE) = Net Margin * Gearing * Asset Turnover
Price to Cash Flow
(PCF)
Price to Cash Flow (PCF) is price at the indicated date divided by cash flow per share.
RoE vs PB
Plot of RoE versus PB at last month end for all FTSE UK All Share stocks in the sector
relative to the stock in question. Data may be limited to the stock in question if there are
currently no stocks in the corresponding FTSE UK All Share sector.
Net Debt Equity
Net Debt Equity is Net Debt as a percentage of common equity. Not calculated if
denominator (common equity) is negative
Absolute
Absolute graphs reflect performance for the stock in question for up to 366 days adjusted
for intervening corporate actions.
EV to EBITDA
EV to EBITDA is Enterprise Value divided by EBITDA (Earnings before Interest and Taxes,
depreciation and amortisation). EV is full company Market Capitalisation at the data date
plus last annual net debt and Preferred Stock. Net Debt is total financial debt less cash
and short-term investments. EBITDA is operating income plus depreciation and
amortisation.
Relative
Relative charts reflect the performance for the stock in question relative to the
corresponding sector of the FTSE All Share Index for up to 366 days, rebased to the start
date. Note that the stock itself may not be a FTSE All share constituent. Relative Chart
may be null if there are no stocks in the corresponding FTSE UK All Share sector.
Dividend Yield %
Dividend Yield reflects the dividend declared per share and/or paid for the security in
question for the most recent fiscal year, divided by the share price.
RSI
Relative Strength Index. Calculated as 100 minus (100 divided by (1+ratio of positive
versus negative time weighted returns)). Reflects 14 day average gains/losses
Return on Equity
(RoE)
Return on Equity is net income over average common equity. Not calculated if
denominator (average common equity) is negative
Valuation History
Charts
Outlier valuation data is not shown to scale as these would distort the chart. Instead, ∥
denotes valuation data which falls outside display truncation limits.
Dividend Payout
Total dividends divided by Net Income expressed as a percentage.
Net Margin
Net Margin is Net Income divided by sales.
Top/Bottom
Valuation Bar
Charts
Reflect data for up to five top and five bottom performers for the valuation metric in
question. Note data may be limited to the stock in question if there are currently no
stocks in the corresponding FTSE UK All Share sector.
A guide to the report is available at http://www.londonstockexchange.com/prices-and-markets/stocks/services-stock/ftse-note.htm.
Midatech Pharma
28 September 2016
For further information visit www.ftse.com, email [email protected] or call your local FTSE office:
Beijing
Boston
Chicago
Dubai
Hong Kong
+86 10 5833 2202
+1 888 747 FTSE (3873)
+1 888 747 FTSE (3873)
+971 4 375 1868
+852 2164 3333
London
Milan
Mumbai
New York
Paris
+44 (0) 20 7866 1810
+39 02 3604 6953
+91 22 6649 4180
+1 888 747 FTSE (3873)
+33 (0)1 53 76 82 89
Rio de Janeiro
San Francisco
Seattle
Shanghai
Sydney
+55 (21) 3736 3726
+1 888 747 FTSE (3873)
+1 888 747 FTSE (3873)
+86 21 6058 9131
+61 (0)2 9293 2864
Tokyo
Toronto
+81 (3) 3581 2811
+1 416 572 7979
© 2016 London Stock Exchange Group companies.
London Stock Exchange Group companies includes FTSE International Limited (“FTSE”), Frank Russell Company (“Russell”), MTS Next Limited (“MTS”), and FTSE TMX Global Debt Capital Markets Inc (“FTSE TMX”). All rights reserved.
“FTSE®”, “Russell®”, “MTS®”, “FTSE TMX®” and “FTSE Russell” and other service marks and trademarks related to the FTSE or Russell indexes are trade marks of the London Stock Exchange Group companies and are used
by FTSE, MTS, FTSE TMX and Russell under licence.
All information is provided for information purposes only. Every effort is made to ensure that all information given in this publication is accurate, but no responsibility or liability can be accepted by the London Stock
Exchange Group companies nor its licensors for any errors or for any loss from use of this publication.
Neither the London Stock Exchange Group companies nor any of their licensors make any claim, prediction, warranty or representation whatsoever, expressly or impliedly, either as to the results to be obtained from the
use of the index/indexes referred to above or the fitness or suitability of the index/indexes for any particular purpose to which it/they might be put. The London Stock Exchange Group companies do not provide investment
advice and nothing in this publication should be taken as constituting financial or investment advice. The London Stock Exchange Group companies make no representation regarding the advisability of investing in any
asset. A decision to invest in any such asset should not be made in reliance on any information herein. Indexes cannot be invested in directly. Inclusion of an asset in an index is not a recommendation to buy, sell or hold
that asset. The general information contained in this publication should not be acted upon without obtaining specific legal, tax, and investment advice from a licensed professional.
No part of this information may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the
London Stock Exchange Group companies. Distribution of the London Stock Exchange Group companies’ index values and the use of their indexes to create financial products require a licence with FTSE, FTSE TMX, MTS
and/or Russell and/or its licensors.
The Industry Classification Benchmark (“ICB”) is owned by FTSE. FTSE does not accept any liability to any person for any loss or damage arising out of any error or omission in the ICB.
Past performance is no guarantee of future results. Charts and graphs are provided for illustrative purposes only. Index returns shown may not represent the results of the actual trading of investable assets. Certain returns
shown may reflect back-tested performance. All performance presented prior to the index inception date is back-tested performance. Back-tested performance is not actual performance, but is hypothetical. The back-test
calculations are based on the same methodology that was in effect when the index was officially launched. However, back- tested data may reflect the application of the index methodology with the benefit of hindsight,
and the historic calculations of an index may change from month to month based on revisions to the underlying economic data used in the calculation of the index.
4 of 4